Inside Eli Lilly: How a Single Drug Class Built the Most Important Pharma Story in 30 Years

Five years ago, Eli Lilly was a competent but unexceptional big pharma franchise. Trulicity (the predecessor GLP-1 for diabetes) was the largest revenue contributor. The oncology pipeline was respectable. The neurology pipeline (donanemab for Alzheimer's) was promising but unproven. The stock traded at a forward multiple of roughly 18-22x, in line with pharma peers.

The transformation came from two specific decisions. First, the development of tirzepatide as a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1 followed Novo Nordisk's path. The dual-mechanism approach delivered superior efficacy in trials, which became the commercial anchor when Mounjaro and later Zepbound launched.

Second, the manufacturing capacity build. Lilly invested aggressively in injectable manufacturing capacity from 2021 onward, well before the demand profile was visible to the market. The capital deployment looked aggressive at the time. It looks visionary in retrospect. The company has since announced more than $20 billion in additional manufacturing investment globally, with new sites in Indiana, North Carolina, Ireland, Germany, and most recently the second Lilly Medicine Foundry announcement.

The combined effect was that when GLP-1 demand exploded in 2023-2024, Lilly was the only major supplier with the manufacturing flexibility to capture incremental share. Novo Nordisk faced (and continues to face) capacity constraints that have limited Wegovy availability in multiple markets. Lilly's capacity advantage compounded into commercial market share.

Two years ago, the question on Lilly was whether the demand for Mounjaro and Zepbound would materialise at the scale the bull case projected. That question is settled. Demand exceeds supply globally and has done so since the Zepbound launch in late 2023.

The new question is the capacity ramp pace. Lilly's manufacturing capacity in 2025 supported roughly $30 billion in incretin franchise revenue. The 2026 capacity ramp is targeting $45-50 billion supportable revenue. The 2027 ramp targets above $60 billion. Each successive capacity tranche requires 18-24 months of construction lead time, which is why the capital deployment that began in 2021 is producing the 2025-2027 capacity curve.

What this means commercially is that Lilly's revenue trajectory through 2027 is largely a function of capacity, not demand. That is an unusual setup for a major pharmaceutical franchise. Most pharma equities are demand-constrained; Lilly is supply-constrained, which compresses the variance on the revenue forecast.

The historical parallel for this dynamic is the 2002-2008 statin cycle, when Lipitor's growth was constrained by formulation and packaging capacity at multiple Pfizer manufacturing sites. The pattern in supply-constrained pharma franchises is that revenue compounds at roughly the capacity ramp pace until either a competitor catches up on supply or the demand curve flattens. Neither has occurred in GLP-1.

At $890 and 26.3x forward earnings, Lilly trades at a meaningful premium to the pharma peer average of roughly 15-17x. The premium is roughly 9 multiple turns. The question is whether the growth profile and margin trajectory justify that premium.

Forward consensus revenue for FY26 is $68 billion. FY27 is $84 billion. Both estimates have been revised up consistently over the past four quarters. The implied two-year compound is roughly 25%. Operating margin is expected to expand from 35% in FY25 to roughly 40% by FY27 as the GLP-1 mix shift completes. The combination produces forward EPS estimates that have been revised up by 30%+ over the past 18 months.

The forward P/E of 26.3x against 25% expected revenue growth and 30%+ EPS growth is, on a PEG basis, around 0.9. That is below 1.0, which is the rough threshold where premium pharma multiples become defensible. By that measure, Lilly is not expensive. It is expensive on absolute multiples, which is a different statement.

The market cap of $846 billion is the largest in pharmaceutical history. The franchise is on a trajectory to become the largest healthcare equity by market cap if the GLP-1 trajectory holds for another two years.

Novo Nordisk remains the second large player in GLP-1 with semaglutide (Ozempic for diabetes, Wegovy for obesity). Novo's commercial position in Europe is stronger than Lilly's; Lilly's commercial position in the US is meaningfully stronger. The two franchises have functionally divided the global market without taking share aggressively from each other.

Novo's pipeline includes CagriSema, the next-generation combination product that delivered mixed Phase 3 readouts in 2024-2025. The data was good but not transformative, which contributed to Novo's relative underperformance versus Lilly through 2025.

Lilly's next-generation pipeline includes retatrutide (a triple-agonist GIP/GLP-1/glucagon), orforglipron (an oral GLP-1), and several follow-on combinations. The retatrutide Phase 3 data, expected in 2026, is the next major catalyst. The trial design produced 24% body weight reduction in mid-stage trials, well above the 22% Zepbound benchmark. If Phase 3 confirms that profile, retatrutide becomes the new commercial anchor for the franchise into the next decade.

The oral GLP-1 segment is the largest open question. Orforglipron has produced solid trial data but oral bioavailability for peptide-mimetic compounds is structurally lower than injectable. The commercial premium that oral commands in the obesity market is uncertain; some patients prefer once-weekly injection over daily oral. The 2026-2027 oral launch will provide the first commercial data point on the relative preference.

The non-GLP-1 portfolio is not a footnote. Verzenio (CDK4/6 inhibitor for breast cancer) is on a $5+ billion revenue trajectory. Jaypirca (BTK inhibitor for chronic lymphocytic leukemia) is in growth mode. Mirikizumab (Omvoh for ulcerative colitis) is the IBD pipeline anchor. Donanemab (Kisunla for early Alzheimer's), launched in 2024, has had a slower commercial rollout than initial estimates but the patient population is large enough that even modest commercial penetration produces meaningful revenue.

The oncology pipeline includes multiple second-generation programs in solid tumours and hematologic malignancies. The franchise has been less prolific than peers in producing breakthrough oncology assets, but the existing portfolio is competent and growing.

The combined effect is that Lilly's non-GLP-1 revenue is on a trajectory of $35-40 billion by FY27, which is meaningful franchise diversification even before counting the next-generation incretin pipeline. The bear argument that Lilly is a one-product franchise materially understates the breadth of the portfolio.